ログイン
ランキング
お知らせ
ログイン
文献詳細
特集 分子を撃つ 神経疾患治療の新しい水平線
文献概要
リツキシマブはB細胞表面のCD20蛋白に対するヒト-マウスキメラ型のモノクローナル抗体製剤である。多発性硬化症，視神経脊髄炎，重症筋無力症，慢性炎症性脱髄性多発根ニューロパチー，中枢神経原発性リンパ腫，その他の自己抗体を伴う自己免疫性神経疾患においてB細胞を制御して治療効果を発揮し，従来の治療法に抵抗を示す難治例でも効果が期待できる。ヒト由来成分比率を高めたオクレリズマブやオファツムマブでは，治療効率と忍容性がさらに高まる。
参考文献
1) 小椋美知則, 飛内賢正（監): リツキサン注使用ガイド. 全薬工業株式会社, 東京, 2010
2) Cragg MS, Walshe CA, Ivanov AO, Glennie MJ: The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 8: 140-174, 2005
3) 小林幸夫: 単クローン抗体を使った分子標的治療. モダンメディア51: 167-173, 2005
4) Deans JP, Li H, Polyak MJ: CD20-mediated apoptosis: signaling through lipid rafts. Immunology 107: 176-182, 2002
5) Janas E, Priest R, Wilde JI, White JH, Malhotra R: Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 139: 439-446, 2005
6) 中島一郎: 分子標的薬による自己免疫性神経疾患の治療. Brain Nerve 65: 1353-1361, 2013
7) Pedersen IM, Buhl AM, Klausen P, Christian H, Jurlander J: The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 99: 1314-1319, 2002
8) Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA: B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44: 1542-1545, 2005
9) Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, et al: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350: 2572-2581, 2004
10) Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, et al: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64: 1215-1226, 2012
11) Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, et al: Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost 11: 481-490, 2013
12) Caramazza D, Quintini G, Abbene I, Coco LL, Malato A, et al: Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura: haemolytic uraemic syndrome. Blood Transfus 8: 203-210, 2010
13) Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, et al: B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358: 676-688, 2008
14) Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, et al: Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63: 395-400, 2008
15) Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, et al: Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66: 460-471, 2009
16) Kappos L: Placebo-controlled multicenter randomized trial of interferonβ-1b in treatment of secondary progressive multiple sclerosis. Lancet 352: 1491-1497, 1998
17) Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group: Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology 56: 1496-1504, 2001
18) Jacob A, Weinshenker BG, Violich I, McLinskey, Krupp L, et al: Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65: 1443-1448, 2008
19) Kim SH, Kim W, Li XF, Jung IJ, Kim HJ: Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 68: 1412-1420, 2011
20) Maddison P, McConville J, Farrugia ME, Davies N, Rose M, et al: The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 82: 671-673, 2011
21) Yoon MS, Chan A, Gold R: Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Ther Adv Neurol Disord 4: 193-200, 2011
22) Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, et al: Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 74: 485-489, 2003
23) Gono T, Matsuda M, Shimojima Y, Ishii W, Yamamoto K, et al: Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti-SGPG IgM antibody. J Clin Neurosci 13: 683-687, 2006
24) 桑原 聡: 難治性末梢神経障害の治療の進歩と展望——免疫性ニューロパチーとCrow-Fukase症候群を中心に. 臨床神経50: 219-224, 2010
25) Briani C, Zara G, Zambello R, Trentin L, Rana M, et al: Rituximab-responsive CIDP. Eur J Neurol 11: 788, 2004
26) Benedetti L, Briani C, Franciotta D, Fazio R, Paolasso I, et al: Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 82: 306-308, 2011
) in multifocal motor neuropathy. J Peripher Nerv Syst 15: 196-201, 2010
28) Graus F, Dalmau J: Paraneoplastic neuropathies. Curr Opin Neurol 26: 489-495, 2013
29) Shams'ili S, de Beukelaar J, Gratama JW, Hooijkaas H, van den Bent M, et al: An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 253: 16-20, 2006
30) Kassar D, Damodaram S, Iyadurai S, Chand P: Rituximab therapy in a patient with recurrent Hashimoto's encephalitis (HE), and progressive encephalomyelitis with rigidity and myoclonus (PERM). Neurology 78 (Meeting abstracts 1): P04.164, 2012
31) Baker M, Das M, Issacs J, Fawcett P, Bates D: Treatment of stiff person syndrome with rituximab. J Neurol Neurosurg Psychiatry 76: 999-1001, 2005
32) Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, et al: Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 66: 470-475, 2007
33) Alpsoy E: New evidence-based treatment approach in Behçet's disease. Patholog Res Int 2012: Article ID 871019, 2012
34) Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, et al: Rituximab in intractable ocular lesions of Behçet's disease; randomized single-blind control study (pilot study). Int J Rheum Dis 13: 246-252, 2010
35) Bomprezzi R, Pati S, Chansakul C, Vollmer T: A case of neurosarcoidosis successfully treated with rituximab. Neurology 75: 568-570, 2010
36) Hardy TA, Barnett MH, Mohamed A, Garsia RJ, Davies L: Severe Bickerstaff's encephalitis treated with rituximab: serum and CSF GQ1b antibodies. J Neuroimmunol 251: 107-109, 2012
37) Birnbaum T, Stadler EA, von Baumgarten L, Straube A: Rituximab significantly improves complete response rate in patients with primary CNS lymphoma. J Neurooncol 109: 285-291, 2012
38) Bazhenova L, Higginbottom P, Mason J: Intravascular lymphoma: a role for single-agent rituximab. Leuk Lymphoma 47: 337-341, 2006
39) Mahler EAM, Blom M, Voermans NC, van Engelen BGM, van Riel PLCM, et al: Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology 50: 2206-2213, 2011
40) Sultan SM, Ng KP, Edwards JC, Isenberg DA, Cambridge G: Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol 26: 887-893, 2008
41) Hauser S, Kappos L, Li D, Calabresi P, O'Connor P, et al: Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial (S30.006). Neurology 78(Meeting Abstracts 1): S30.006, 2012
42) Nowak RJ, Dicapua DB, Zebardast N, Goldstein JM: Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord 4: 259-266, 2011
43) Badari A, Farolino D, Nasser E, Mehboob S, Crossland D: A novel approach to paraneoplastic intestinal pseudo-obstruction. Support Care Cancer 20: 425-428, 2012
掲載誌情報
